SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 40-F/A - Registration statement [Section 12] or Annual Report [Section 13(a), 15(d)]: [Amend]
SEC Accession No. 0001062993-18-001503
Filing Date
2018-04-04
Accepted
2018-04-04 17:23:41
Documents
71
Period of Report
2017-12-31

Document Format Files

Seq Description Document Type Size
1 FORM 40-F/A form40fa.htm 40-F/A 15740
  Complete submission text file 0001062993-18-001503.txt   4003109

Data Files

Seq Description Document Type Size
2 XBRL INSTANCE FILE tril-20171231.xml EX-101.INS 865814
3 XBRL SCHEMA FILE tril-20171231.xsd EX-101.SCH 74276
4 XBRL CALCULATION FILE tril-20171231_cal.xml EX-101.CAL 56322
5 XBRL DEFINITION FILE tril-20171231_def.xml EX-101.DEF 329003
6 XBRL LABEL FILE tril-20171231_lab.xml EX-101.LAB 482674
7 XBRL PRESENTATION FILE tril-20171231_pre.xml EX-101.PRE 358386
Mailing Address 2488 DUNWIN DRIVE MISSISSAUGA A6 L5L 1J9
Business Address 2488 DUNWIN DRIVE MISSISSAUGA A6 L5L 1J9 (416) 595-0627
Trillium Therapeutics Inc. (Filer) CIK: 0001616212 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A6 | Fiscal Year End: 1214
Type: 40-F/A | Act: 34 | File No.: 001-36596 | Film No.: 18738232
SIC: 2834 Pharmaceutical Preparations